We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease (CARR-COV-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04521322
Recruitment Status : Unknown
Verified August 2020 by Ariel Dogliotti, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno.
Recruitment status was:  Recruiting
First Posted : August 20, 2020
Last Update Posted : August 21, 2020
Sponsor:
Collaborator:
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Information provided by (Responsible Party):
Ariel Dogliotti, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Coronaviruses are enveloped viruses with an RNA genome. Carrageenans are sulfate polysaccharides synthesized by red algae. Studies conducted in adults and children with the common cold showed the effectiveness of the use of Carrageenan in nasal spray.

For decades, the antiviral action of Carrageenans has been described in numerous studies with different viruses that infect humans: herpes viruses types 1 and 2, human immunodeficiency virus, human papillomavirus, H1N1 influenza virus, dengue virus, rhinovirus, hepatitis A virus, and enteroviruses. Studies on the dynamics of COVID-19 disease show an intense and rapid pharyngeal multiplication in the first 3-5 days of the onset of symptoms, prior to the onset of pulmonary disease.

Finally, this molecule has shown a viricidal effect against SARS-Cov2 in vitro. All this underscores the potential value of a therapy that inhibits the virus in the rhinopharynx.


Condition or disease Intervention/treatment Phase
Covid19 Drug: Iota-Carrageenan Phase 4

Detailed Description:
This is a multicenter, randomized, double-blind, placebo-controlled trial assessing the use a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 disease in health-workers.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicenter, randomized, double blind compared vs placebo
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)
Actual Study Start Date : July 24, 2020
Estimated Primary Completion Date : October 30, 2020
Estimated Study Completion Date : November 30, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Control
Participants in this arm will receive a nasal spray with placebo
 Drug: Iota-Carrageenan
Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
Other Name: Placebo
Experimental: Experimental
Participants in this arm will receive a nasal spray with Iota-Carrageenan
 Drug: Iota-Carrageenan
Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
Other Name: Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. diagnose of COVID19 disease [ Time Frame: 28 days ]
    COVID 19 disease will be defined for clinical diagnose and positive Polymerase Chain Reaction test


Secondary Outcome Measures :
  1. Progression to a more severe disease state, defined as need for oxygen therapy. [ Time Frame: 28 days ]
    number of subjects who develop severe COVID19 disease

  2. lasting of disease [ Time Frame: 28 days ]
    number of days with clinical symptoms

  3. Incidence of COVID-19 disease onset in the first week after treatment [ Time Frame: 1 week after finishing treatment ]
    number of subjects who develop the disease within one week after finishing treatment


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • physician, nurses, and physical therapist who usually attend hospitalized COVID19 patients.
  • No more than 48 hours since he/she assisted a COVID-19 patient
  • Able to understand and give written informed consent

Exclusion Criteria:

  • Participation in any other clinical trial of an experimental treatment for COVID-19
  • Not having a cell phone with WhatsApp for remote monitoring
  • Hypersensitivity or known allergy to any component of the product
  • Pregnancy or lactation
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04521322


Contacts
Layout table for location contacts
Contact: Mónica Lombardo, MD 005491141763599 mlombardo@nobeltri.com
Contact: Ricardo Valentini, MD 005491162036790 deptomedicina2@gmail.com

Locations
Layout table for location information
Argentina
centro de educación médica e investigaciones clinicas (CEMIC) Recruiting
Buenos Aires, Capital Federal, Argentina, 1425
Contact: Mónica Lombardo, MD    541152990600    mlombardo@nobeltri.com   
Contact: Ricardo c Valentini    +541152990600    rvalentini@cemic.edu.ar   
Sponsors and Collaborators
Ariel Dogliotti
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Investigators
Layout table for investigator information
Study Director: Juan Figueroa, MD Instituto Milstein-CONICET
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Ariel Dogliotti, PHYSICIAN, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
ClinicalTrials.gov Identifier: NCT04521322    
Other Study ID Numbers: CEMIC
First Posted: August 20, 2020    Key Record Dates
Last Update Posted: August 21, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases